Exhibit 99.1

             CAVIT SCIENCES, INC. ANNOUNCES ASSET PURCHASE AGREEMENT

     BOCA RATON, FL, MAY 30, 2008--CAVIT SCIENCES,  INC. ("Cavit") (OTCBB: CVIT)
announced today that it completed an Asset Purchase  Agreement with  Alternecare
Health Products, Inc. ("ALTERNECARE(TM)") on May 28, 2008.

ALTERNECARE(TM)  is an innovator and leader in combining rapid home  diagnostics
with therapeutic nutraceutical based solutions, has penetrated the retail market
in the US and has  initiated the process to establish  itself in the  e-commerce
marketplace.   Cavit  acquired  ALTERNECARE(TM)'s  inventory,   customer  lists,
existing relationships, trademark and website.

Most  importantly,  Cavit acquired the consulting  services of Ismael  Gonzalez,
ALTERNECARE(TM)'s  President.  Ismael has over 15 years of management experience
in the natural products  industry.  He has held business  development roles with
top  companies  ranging  from   manufacturing  to  distribution.   His  business
development expertise will be instrumental in Cavit's future.

ALTERNECARE(TM)'s  product line joins Cavit's  other two  supplement  lines,  MD
SOLUTION(TM) and AMERICARE HEALTH PRODUCTS(TM). Its brand awareness and presence
in the retail market will assist the launch of Cavit's  additional  products and
lines.

An  overview  of  ALTERNECARE(TM)'s   products  is  available  on  its  website:
www.alternecare.com

Cavit  Sciences,  Inc.  ("Cavit")  is a  biotechnology  company  that has  three
developed  supplement  lines with products that enhance,  improve,  maintain and
support the body by beneficially  effecting various conditions and is engaged in
developing treatments and prevention for cancer, viral infections, opportunistic
infections,  related  diseases and the immune system.  Product  information  and
updates  will soon be  available  on  Cavit's  website.  Additional  information
regarding our supplement lines,  treatment,  development and Company information
is available on the Company's website at: www.cavitsciences.com

Statements  contained herein that are not historical fact may be forward-looking
statements  within the meaning of Section 27A of the  Securities Act of 1933 and
Section  21E of the  Securities  Exchange  Act of 1934,  that are  subject  to a
variety of risks and uncertainties. There are a number of important factors that
could  cause  actual  results  to differ  materially  from  those  projected  or
suggested  in any  forward-looking  statements  made  by  Cavit.  These  factors
include,  but are not limited to: (i) the ability of Cavit to successfully raise
financing,  (ii)  the  ability  of  Cavit  to  finalize  its  manufacturing  and
distribution  facilities,  and  (iii)  the  ability  of  Cavit  to  successfully
commercialize  its products in certain  markets.  Additional  factors that would
cause actual results to differ  materially  from those projected or suggested in
any  forward-looking  statements  are  contained  in  Cavit's  filings  with the
Securities and Exchange Commission,  including those factors discussed under the
caption "Risk Factors" for Cavit on Form 10K-SB filed on April 18, 2008..

CONTACT:

Colm J. King, CEO      (561) 544-6988
Cavit Sciences, Inc.   www.cavitsciences.com